Effect of Longbishu Capsule (癃闭舒胶囊) plus doxazosin on benign prostatic hyperplasia: A randomized controlled trial

Chun-sheng Song; Jun Guo; De-gui Chang; Lei Chen; Rui Zhang; Jia-you Zhao; Fu Wang; Qiang Zhang

doi:10.1007/s11655-014-1844-0

Your Location：

Home >

Browse articles >

Effect of Longbishu Capsule (癃闭舒胶囊) plus doxazosin on benign prostatic hyperplasia: A randomized controlled trial

Updated：2021-08-27

- Effect of Longbishu Capsule (癃闭舒胶囊) plus doxazosin on benign prostatic hyperplasia: A randomized controlled trial
- Chinese Journal of Integrative Medicine Vol. 20, Issue 11, Pages: 818-822(2014)
- Affiliations：
  
  1. Graduate School of China Academy of Chinese Medical Sciences,Beijing,China
  2. Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
  3. Department of Urology and Andrology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu,China
  4. Department of Urology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai,China
  5. Department of Andrology, the Second Affiliated Hospital to Heilongjiang University of Traditional Chinese Medicine,Harbin,China
- Author bio：
- Funds：
  
  Supported by the Project of Science Research for the 11th Five Year Plan (No. 2007BAI20B044)
- DOI：10.1007/s11655-014-1844-0
  CLC：
- Published：2014，
  
  Published Online：18 June 2014，
Scan for full text
Song, Cs., Guo, J., Chang, Dg. et al. Effect of Longbishu Capsule (癃闭舒胶囊) plus doxazosin on benign prostatic hyperplasia: A randomized controlled trial., Chin. J. Integr. Med. 20, 818–822 (2014). https://doi.org/10.1007/s11655-014-1844-0

Chun-sheng Song, Jun Guo, De-gui Chang, et al. Effect of Longbishu Capsule (癃闭舒胶囊) plus doxazosin on benign prostatic hyperplasia: A randomized controlled trial. [J]. Chinese Journal of Integrative Medicine 20(11):818-822(2014)
Song, Cs., Guo, J., Chang, Dg. et al. Effect of Longbishu Capsule (癃闭舒胶囊) plus doxazosin on benign prostatic hyperplasia: A randomized controlled trial., Chin. J. Integr. Med. 20, 818–822 (2014). https://doi.org/10.1007/s11655-014-1844-0 DOI：

Chun-sheng Song, Jun Guo, De-gui Chang, et al. Effect of Longbishu Capsule (癃闭舒胶囊) plus doxazosin on benign prostatic hyperplasia: A randomized controlled trial. [J]. Chinese Journal of Integrative Medicine 20(11):818-822(2014) DOI： 10.1007/s11655-014-1844-0.

摘要

To investigate the effect of Longbishu Capsule (癃闭舒胶囊

LBS)

doxazosin

and combination therapy on benign prostatic hyperplasia (BPH). A randomized

double-blind

multi-center parallel trial was conducted involving 360 patients in hospitals in Beijing (108 cases)

Heilongjiang (90 cases)

Sichuan (90 cases)

Shanghai (72 cases)

China. They were randomly assigned with central randomization method to group A (LBS placebo plus doxazosin)

group B (LBS plus doxazosin) or group C (LBS plus doxazosin placebo)

120 cases for each group. The international prostate symptom score

maximum urinary flow rate

postvoid residual urine volume and prostate volume were measured for evaluating the efficacy of the three treatments. At baseline

there was no significant difference in the measured variables among the three groups. After 12-month treatment

the three groups showed significant improvements in IPSS and maximum urinary flow rate from baseline (P<0.01). Although postvoid residual urine volume was not significantly different from the baseline in group A (P>0.05)

it significantly decreased in group B and C (P<0.05). The incidence of adverse events were similar among the three groups. The treatment of LBS alone or LBS plus doxazosin was able to significantly improve IPSS in patients with BPH. The treatments may reduce the increase in prostate volume and postvoid residual urine volume as well.

Abstract

To investigate the effect of Longbishu Capsule (癃闭舒胶囊

LBS)

doxazosin

and combination therapy on benign prostatic hyperplasia (BPH). A randomized

double-blind

multi-center parallel trial was conducted involving 360 patients in hospitals in Beijing (108 cases)

Heilongjiang (90 cases)

Sichuan (90 cases)

Shanghai (72 cases)

China. They were randomly assigned with central randomization method to group A (LBS placebo plus doxazosin)

group B (LBS plus doxazosin) or group C (LBS plus doxazosin placebo)

120 cases for each group. The international prostate symptom score

maximum urinary flow rate

postvoid residual urine volume and prostate volume were measured for evaluating the efficacy of the three treatments. At baseline

there was no significant difference in the measured variables among the three groups. After 12-month treatment

关键词

benign prostatic hyperplasiacombination therapyLongbishu Capsuledoxazosinclinical progressionChinese Medicine

Keywords

benign prostatic hyperplasiacombination therapyLongbishu Capsuledoxazosinclinical progressionChinese Medicine

references

Kumar R, Malla P, Kumar M. Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia. Expert Opin Drug Discov 2013;8:1013–1027.

McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–2398.

Cohen SA, Parsons JK. Combination pharmacological therapies for the management of benign prostatic hyperplasia. Drugs Aging 2012;29:275–284.

Wang ZH. Effect of Longbishu Capsule on benign prostatic hyperplasia: an observational study. Nat J Androl 2005;11:873,879.

Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549–1557.

Zhang XH, Wang XH, Wang G, Wei Q, Xu CL, Xue W, et al. Diagnostic and treatment guidelines on benign prostatic hyperplasia of Chinese. Chin J Surgy (Chin) 2007;45:1704–1707.

Ministry of Health of People’s Republic of China. Guiding principle of clinical research of Chinese new drug (the first series). 1993:171.

Roehrborn CG, Girman CJ, Rhodes T, Hanson KA, Collins GN, Sech SM, et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997;49:548–557.

Trachtenberg J. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient’s risk profile for progression. BJU Int 2005;95(Suppl 4):6–11.

Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006:175:1422–1427.

Kolman C, Girman CJ, Jacobsen SJ, Lieber MM. Distribution of postvoid residual urine in randomly selected men. J Urol 1999;161:122–127.

Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000;21:167–189.

McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557–563.

Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996;155:595–600.

Wu SL, Yang CS, Duan JH, Xiao YX, Guo HF. Effecting of mechanism of Chinese drug Longbishu Capsule on patients with weaken destrusor. J Clin Urol 2010;25:464–465.

McNeill SA. Does acute urinary retention respond to alphablockers alone? Eur Urol 2001;39(Suppl 6):7–12.

O’Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 2003;62:15–23.

Masumori N, Tsukamoto T, Horita H, Sunaoshi K, Tanaka Y, Takeyama K, et al. α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study Int J Urol 2013;20:421–428.

FULL TEXT LINK

More>

Views

766

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: A randomized controlled trial

Qianliening capsule (前列宁胶囊) inhibits human prostate cell growth via induction of mitochondrion-dependent cell apoptosis

Chinese medicine as complementary therapy for female infertility

Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma

Gefitinib plus Fuzheng Kang’ai Formula (扶正抗癌方) in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial

Related Author

No data

Related Institution

Department of Traditional Chinese Medicine, Zhongshan Hospital, Xiamen University

Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine

Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine

Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine

Department of Integrative Medicine, Fujian University of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰